InSightec's uterine fibroid therapy to replace 60% of surgeries
This article was originally published in Clinica
Executive Summary
Israeli company InSightec received US FDA approval for ExAblate 2000, its magnetic resonance-guided focused ultrasound procedure for treating uterine fibroids in October. Speaking at the RSNA meeting in Chicago last month, the company's CEO, Dr Jacob Vortman and marketing manager, Lyn Golumbic, told Daniel Barry about the potential for the technology, which they say could one day replace most surgical procedures for the condition